Naxpar Pharma Private Limited - Due diligence report

A 360° intelligence report on Naxpar Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals …

2004-02-10 Mumbai, Maharashtra Active Unlisted Active Compliant
Share
NP Naxpar Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Naxpar Pharma — 360° Intelligence Report

Generated from MCA filings & public records
83/100
Trust Score
Low Risk

Naxpar Pharma is assessed as Low Risk with a Trust Score of 83/100. Naxpar Pharma is an active private limited indian non-government company incorporated in 2004, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Naxpar Pharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
83/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
72/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
85/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
90/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 55/100 Moderate
  • Open charges exceed net worth - secured lenders rank ahead.
  • Profitable - internal accruals available.

Charges position: 18 open (125.65 cr) · 2 satisfied (17.47 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others10 48.0 cr
Apna Sahakari Bank Ltd2 48.0 cr
Hdfc Bank Limited6 48.0 cr
State Bank Of India1 48.0 cr
Apna Sahakari Bank Limited1 48.0 cr
Compliance Score: 72/100 Moderate
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 4 court forum(s).
  • Delayed payments to MSME suppliers disclosed (204 disclosure(s)).
  • 3 active GST registration(s).
Legal cases on record (4)
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
HARISH SUNDERLAL PANPALIA 01234567 Director 01/04/2018 6 yrs Approved
MIHIR PRAKASH SHAH 01234567 Director 01/04/2018 6 yrs Approved
YOGESH KANTILAL VARIA 01234567 Director 01/04/2018 6 yrs Approved
BAIJU MAHASUKHLAL SHAH 01234567 Director 01/04/2018 6 yrs Approved
PRAKASH MAHASUKHLAL SHAH 01234567 Director 01/04/2018 6 yrs Approved
  • 5 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Parnax Lab Limited
Subsidiaries
-
Group entities
-
Capital events
2 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Parnax Lab Limited Holding Company 74.00%

Key managerial personnel: MIHIR PRAKASH SHAH (Whole-time director) · BAIJU MAHASUKHLAL SHAH (Whole-time director) · PRAKASH MAHASUKHLAL SHAH (Whole-time director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 90 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
Profit expanded 1.42 year-on-year.
Asset base grew 2.1x - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 22+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 24% in a year.
18 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 1.16 cr.
4 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence78/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment68/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 18 open charge(s) of 125.65 cr already registered.
  • Compliance record supports lending.
Investor view86/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 4 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
26 Sep 2025
Last AGM held
Annual general meeting
30 Jun 2025
Charge created
Hdfc Bank Limited - 2.91 cr
08 Jun 2025
Charge satisfied
Hdfc Bank Limited
31 Mar 2025
Latest balance sheet
Filed with ROC
13 Dec 2023
Charge created
Hdfc Bank Limited - 14.16 cr
28 Sep 2023
Director ceased
HARISH SUNDERLAL PANPALIA
11 Aug 2023
Director appointed
HARISH SUNDERLAL PANPALIA (Director)
25 Jul 2023
Charge created
Hdfc Bank Limited - 9.77 Lakh
24 Dec 2021
Charge created
Others - 4.00 cr
30 Nov 2021
Director ceased
YOGESH KANTILAL VARIA
29 Oct 2021
Charge created
Hdfc Bank Limited - 78.91 Lakh
31 Aug 2021
Charge created
Hdfc Bank Limited - 22.50 Lakh
08 Jun 2021
Charge created
Others - 6.00 cr
28 May 2021
Director appointed
YOGESH KANTILAL VARIA (Director)
27 Feb 2021
Director ceased
MANHARBHAI NAVALCHAND JHAVARI
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - leverage worth monitoring.
Net worth is positive.
5 active director(s) / partner(s); board looks stable and experienced.
3 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Melody Healthcare Private Limited U24239MH2006PTC163460 Mumbai, Maharashtra, India
Uperp U24232TN2007PLC063446 Chennai, Tamil Nadu, India
Ashish Life Science U24100MH1992PTC064810 Palghar, Maharashtra, India
Apothecon Pharmaceuticals U24232GJ2007PTC050825 Taluka Padra, Gujarat, India
Myra Hygiene Products Private Limited U74994WB2018PTC228326 Kolkata, West Bengal, India
Ir U24100HR2011PTC043817 Gurugram, Haryana, India
Monopoly Innovations U15132MH2014PLC253906 Raigad, Maharashtra, India
J Duncan U24230MH2003PTC139202 Shahapur, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Naxpar Pharma before audits and certifications: compliance score 72/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Naxpar Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 90/100, margin trends, ownership structure and peer set for Naxpar Pharma - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 83/100, distress signals and MSME payment-delay disclosures - know whether Naxpar Pharma pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (4 case(s) on record), regulatory flags, charge documents trail and director networks for Naxpar Pharma - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Naxpar Pharma an active company?

Naxpar Pharma has MCA status “Active” with a compliance score of 72/100 (Moderate).

Is Naxpar Pharma financially healthy?

Naxpar Pharma has a Financial Health Score of 85/100 (Low Risk) based on its filed financial statements.

Should I do business with Naxpar Pharma?

Its overall Trust Score is 83/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Naxpar Pharma?

The ultimate holding entity is Parnax Lab Limited. 5 active director(s) are on record.

Does Naxpar Pharma have loans or charges against its assets?

18 open charge(s) are registered against its assets, and 2 earlier charge(s) stand satisfied.

Is Naxpar Pharma up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 72/100 (Moderate).

Is it risky to lend to Naxpar Pharma?

Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.